XSTEM is under clinical development by Xintela and currently in Phase II for Osteoarthritis. According to GlobalData, Phase II drugs for Osteoarthritis have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XSTEM’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XSTEM overview

XSTEM is under development for the treatment of knee osteoarthritis, difficult-to-heal chronic venous leg ulcers, acute respiratory distress syndrome (ARDS) and unspecified indication. The drug candidate is administered by intraarticular and topical route. The therapeutic candidate comprises of allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cells. It is developed based on XINMARK protein marker technology.

Xintela overview

Xintela is a biopharma company that develops therapy for the treatment of leg ulcers. Its technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also offers analytical test such as XACT (Xintela Assay for Cell Therapy), used for quality assurance of methods and cells. Xintela’s analytical test finds application in research and development activities for stem cell products. It develops therapeutic antibodies, which bind to cancer cells. The company conducts its research in the fields of regenerative medicine and cancer with significance on cartilage damage such as osteoarthritis and brain cancer. Xintela is headquartered in Lund, Sweden.

For a complete picture of XSTEM’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.